Study guide

13.3 Packaging and the Poison Prevention Packaging Act

Connecticut Multistate Pharmacy Jurisprudence Examination CT MPJE

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Connecticut MPJE 1.2 Application, Fees, ATT, and Pearson VUE 1.3 Blueprint, Scoring, Retakes, and Study Strategy

2 Connecticut Regulatory Structure

2.1 DCP and the Commission of Pharmacy 2.2 Chapter 400j, 420b/420c, and RCSA 20-576 2.3 Federal vs Connecticut Law (More Restrictive Rule)

3 Pharmacist Licensure, Interns, PIC, and CE

3.1 Pharmacist Qualifications and Exam Path 3.2 Interns, Score Transfer, and Reciprocity 3.3 Pharmacist-in-Charge / Pharmacist Manager 3.4 License Renewal and Continuing Education

4 Technicians and Non-Pharmacist Personnel

4.1 Technician Registration and Certification 4.2 Community Technician Ratios (20-576-36) 4.3 Institutional Ratios and Advanced Pharmacy Technicians 4.4 Technician Limitations, Interns, and Unlicensed Staff

5 Discipline, Impairment, and Unlicensed Practice

5.1 Disciplinary Grounds (CGS § 20-579) 5.2 Impaired Practitioner Reporting and Programs 5.3 Unlicensed Practice, Penalties, and Appeals

6 Federal Drug Law Foundations

6.1 FDCA, Adulteration, and Misbranding 6.2 FDA Approval, Recalls, and OTC vs Rx 6.3 DSCSA, HIPAA, OBRA ’90, and PPPA

7 Federal Controlled Substances

7.1 CSA Schedules and Definitions 7.2 DEA Registration and Forms 222, 106, 41 7.3 Federal Controlled-Substance Prescription Rules 7.4 Inventory, Theft, Loss, and Disposal

8 Prescription Issuance in Connecticut

8.1 Who May Prescribe in Connecticut 8.2 Noncontrolled Prescription Form and Content 8.3 Controlled Prescriptions and the EPCS Mandate

9 Refills, Partial Fills, and Opioid Limits

9.1 Refill Authority (Noncontrolled and CIII–V) 9.2 Partial Fills of Schedule II Prescriptions 9.3 Connecticut Opioid Supply Limits (7-day / 5-day)

10 Administration, CDTM, and Standing Orders

10.1 Pharmacist Immunization Authority 10.2 Collaborative Drug Therapy Management 10.3 Naloxone and Opioid Antagonist Access 10.4 Emergency and Hormonal Contraception

11 Counseling, Confidentiality, and Returns

11.1 Counseling and Offer to Counsel 11.2 HIPAA and Connecticut Confidentiality 11.3 Return, Reuse, and Take-Back

12 Corresponding Responsibility and DUR

12.1 Corresponding Responsibility and Legitimate Medical Purpose 12.2 Prospective Drug Utilization Review 12.3 Exceptions and Conditions Prohibiting Dispensing

13 Transfers, Labeling, Packaging, and Delivery

13.1 Transferring Prescriptions 13.2 Labeling of Dispensed Drugs 13.3 Packaging and the Poison Prevention Packaging Act 13.4 Delivery of Drugs

14 CPMRS, Substitution, and Nonprescription Drugs

14.1 CPMRS Query and Reporting 14.2 Generic and Biosimilar Substitution 14.3 CMEA and Behind-the-Counter Products 14.4 OTC Labeling, Hazardous, and Restricted Nonprescription Drugs

15 Ordering, Records, and Inventories

15.1 Ordering and Acquisition (DEA 222/CSOS) 15.2 Distribution and DSCSA Records 15.3 Recordkeeping Content and Three-Year Retention 15.4 Controlled-Substance Inventories and CT Perpetual CII

16 Storage, Security, and Hazardous Drugs

16.1 Controlled-Substance Storage and Security 16.2 Hazardous Drugs (USP <800>, NIOSH) 16.3 Non-Pharmacist Access to Drugs

17 Compounding and Central Fill

17.1 Nonsterile Compounding (USP <795>, RCSA 20-576-69) 17.2 Sterile Compounding (USP <797>, RCSA 20-576-64) 17.3 Central Fill, 503A, and 503B Outsourcing

18 Pharmacy Permits and Practice Settings

18.1 Pharmacy License, Hours, Manager, and Signage 18.2 Nonresident, Hospital, Nuclear, and Automated Dispensing 18.3 Inspection, Closure, and Facility Discipline

13.3 Packaging and the Poison Prevention Packaging Act

Key Takeaways Explain This Topic AI

The Poison Prevention Packaging Act requires special (child-resistant) packaging for oral prescription drugs intended for human use (16 CFR 1700.14(a)(10)) and for oral controlled substances (16 CFR 1700.14(a)(4)), unless a listed exemption applies.

15 U.S.C. § 1473(b) lets a prescriber direct, or the purchaser request, a non-child-resistant (easy-open) package. Either the patient or the prescriber may request it; the pharmacist does not default the entire caseload to snap-caps.

Sublingual nitroglycerin is expressly exempt (16 CFR 1700.14(a)(10)(i)). Other high-yield exemptions include sublingual/chewable isosorbide dinitrate 10 mg or less and mnemonic oral-contraceptive packs.

Document the easy-open request in the profile. Connecticut has not published a unique easy-open form, but an undocumented standing waiver is how a later pediatric ingestion becomes an unprovable CPSC problem.

PPPA special packaging applies to household substances. Unit-dose packaging used for administration inside an institution is not household use; sending that same oral drug home with the patient returns CRC duty unless an exemption or a documented request applies.

Last updated: August 2026

Why the cap is a scored federal rule

Quick Answer: The Poison Prevention Packaging Act (PPPA) requires child-resistant (special) packaging for oral prescription drugs ( 16 CFR 1700.14(a)(10) ) and oral controlled substances ( (a)(4) ). 15 U.S.C. § 1473(b) allows a noncomplying (easy-open) package only when the prescriber directs it or the purchaser requests it. Sublingual nitroglycerin is exempt ( 16 CFR 1700.14(a)(10)(i) ). Document the easy-open request. Institutional unit-dose for on-site administration is not household packaging; a vial going home is.

NABP Competency 3.6 is packaging. Chapter 6.3 introduced PPPA next to DSCSA and HIPAA. This section is the Saturday decision : CRC vial, snap-cap, manufacturer mnemonic pack, or unit-dose cassette. Connecticut has not enacted a stricter statewide CRC statute that replaces the federal Act. More-restrictive still wins if a future Connecticut rule appears; today the CPSC text is the exam’s packaging law.

The PPPA (15 U.S.C. §§ 1471–1477) is a CPSC statute, not an FDA labeling statute and not a Commission of Pharmacy regulation. Special packaging means a package designed to be significantly difficult for children under five to open or to obtain a toxic amount within a reasonable time, and not difficult for normal adults to use properly ( 15 U.S.C. § 1471 ; test protocol 16 CFR 1700.20 ). Adult-friendly CRC exists; “the patient is 82” is not , by itself, a waiver.

Default — CRC for oral Rx drugs

16 CFR 1700.14(a)(10) requires special packaging for any drug for human use that is in a dosage form intended for oral administration and that federal law requires to be dispensed only on prescription, except the listed exemptions. 16 CFR 1700.14(a)(4) separately requires special packaging for oral controlled substances . Inhalers, topicals, injectables, and ear/eye drops are not in the oral-Rx sentence. A community pharmacist who puts every oral tablet in a snap-cap because “seniors prefer them” is running an illegal default, not a PPPA exception.

The dispensing pharmacist is responsible for the package that leaves the pharmacy. Manufacturer CRC stock bottles used as the dispensed container can satisfy the Act if they still meet the protocol after the pharmacist has opened and resealed them. A bulk stock bottle poured into a non-CRC vial, without a request or exemption, is the violation.

Who may waive CRC — patient or prescriber, not the pharmacist’s convenience

15 U.S.C. § 1473(b) (PPPA section 4(b)) is the waiver. For a household substance subject to a special-packaging standard and dispensed pursuant to an order of a physician, dentist, or other licensed practitioner authorized to prescribe, the substance may be dispensed in noncomplying packages only when directed in such order or when requested by the purchaser .

Consequences for the MPJE:

The patient (purchaser) may request easy-open for one prescription or, if the request is clear, for all of that patient’s oral medications. CPSC has long treated a specific all-prescriptions request as lawful. A silent profile is not a blanket waiver.

The prescriber may direct non-CRC on that order (“no safety cap”). That direction is drug-specific unless the order is written more broadly. It does not authorize the pharmacy to convert every other drug in the profile.

The pharmacist may not decide, unilaterally, that arthritis or age makes CRC optional. Offer CRC; honor a request .

A caregiver picking up is not automatically the “purchaser.” Get the patient’s request on file when someone else is at the window, or follow a prescriber’s written direction.

Document the request. The PPPA does not prescribe a Connecticut-specific form, and Chapter 400j has not published a unique easy-open affidavit. An undocumented “she always wants snap-caps” is how a later toddler ingestion becomes an unprovable file. Note who requested (patient or prescriber), when , and whether it is this Rx only or a standing patient-level request. Revisit a standing waiver when the household changes (grandchildren in the home).

16 CFR 1700.5 ’s “This Package for Households Without Young Children” statement is the manufacturer one-size noncomplying OTC rule. It is not a license to label every pharmacy vial that way and skip CRC. Chapter 6.3 already used that trap; do not reuse it as the outpatient default.

Listed exemptions — SL nitroglycerin is the prototype

16 CFR 1700.14(a)(10) then lists products that need not be in special packaging. High-yield for this exam:

Sublingual dosage forms of nitroglycerin — (a)(10)(i) . The classic easy-open manufacturer bottle. Do not pour SL NTG into a CRC vial “to be extra safe” if that delays self-administration in angina; the exemption exists because time to open is a clinical risk.

Sublingual and chewable isosorbide dinitrate in strengths of 10 mg or less — (a)(10)(ii) .

Mnemonic oral-contraceptive packs that rely solely on progestogen or estrogen — (a)(10)(iv) ; hormone-replacement products on the same theory — (a)(10)(xxi) .

Selected unit-dose potassium supplements (≤ 50 mEq/unit), certain pancrelipase preparations, and other listed packages (erythromycin ethylsuccinate quantity limits, sodium fluoride package limits, and others in (iii)–(xxiv)).

An exemption is product-specific . Exempt SL nitroglycerin does not exempt the same patient’s oral isosorbide tablets that are not SL/chewable 10 mg or less. Exempt oral contraceptives in the manufacturer mnemonic pack do not exempt a bulk vial of the same hormone if the pharmacy repacks it into a 30-count bottle — unless the patient or prescriber requests easy-open or another exemption applies.

  • Situation CRC required? Why
  • Oral lisinopril to a community patient, no request on file Yes 16 CFR 1700.14(a)(10) default

Same lisinopril, patient requests snap-caps; request noted No (noncomplying allowed) 15 U.S.C. § 1473(b) purchaser request

  • Prescriber writes “easy-open vial” on one prescription No , for that drug § 1473(b) practitioner direction
  • SL nitroglycerin in manufacturer bottle No 16 CFR 1700.14(a)(10)(i)
  • Oral oxycodone tablets going home Yes , unless request/exemption Oral CS are also (a)(4)

Unit-dose cassette administered in a hospital or LTCF PPPA household standard does not apply to on-site institutional administration Household-substance definition; not a discharge vial

Same oral drug dispensed at discharge to the household Yes , unless request/exemption It is now a household substance

Institutional unit-dose versus household use

The PPPA regulates household substances — substances customarily used or stored in or about the household ( 15 U.S.C. § 1471 ). Drugs administered by staff inside a hospital, nursing facility, or similar institution are not being packaged for household use. Unit-dose (and unit-of-use) systems used for institutional administration are therefore not required to wear community CRC vials. That matches how 21 CFR 1306.14(c) / 1306.24(c) treat institutional CS labeling when the drug is never in the ultimate user’s possession before administration.

The trap is discharge and leave of absence . A seven-day unit-dose card handed to the patient to take home is household packaging. Apply CRC, a listed exemption, or a documented easy-open request. Do not cite “we’re a hospital pharmacy” as a blanket PPPA waiver for every bag that walks out the lobby.

Connecticut community technician ratios already treat unit-dose / unit-of-use as a distinct workflow ( RCSA § 20-576-36 ; Chapter 4). That ratio rule is not a packaging exemption. Packaging still follows CPSC when the product is for household use.

Realistic Connecticut scenarios

A 78-year-old in Norwalk asks for snap-caps on her lisinopril only . Document patient request, this prescription . Keep her warfarin in CRC unless she (or the prescriber) also waives that drug. Refusing all snap-caps because “Connecticut never allows them” is false. Defaulting her entire profile to snap-caps because she is elderly, with no request , is also false.

A New Haven cardiology prescription for SL nitroglycerin 0.4 mg arrives. Dispense the manufacturer’s non-CRC bottle. Counseling still covers storage, expiration after opening if the manufacturer so states, and when to call 911 — auxiliary labels and CRC theory do not replace that discussion (Chapter 11).

A Hartford hospital pharmacy sends a 24-hour unit-dose drawer of oral medications to an inpatient unit. PPPA household CRC is not the test. The same pharmacist filling a discharge bottle of oral oxycodone for the household must use CRC unless the patient or prescriber has requested otherwise. 16 CFR 1700.14(a)(4) does not care that the patient was an inpatient this morning.

Official anchors

15 U.S.C. § 1473(b) — prescriber direction or purchaser request for noncomplying packaging.

16 CFR 1700.14 — oral Rx drugs and oral CS requiring special packaging; SL nitroglycerin and other exemptions.

16 CFR 1700.15 / 1700.20 — special-packaging standards and child-test protocol.